Superfluid Dx is developing a blood-based diagnostic platform utilizing cf-mRNA technology to detect Alzheimer’s Disease at its earliest stages, enabling timely intervention and personalized treatment options. This minimally invasive approach replaces traditional diagnostic methods, such as spinal taps and brain scans, with a simple blood test that allows for ongoing monitoring of disease progression.
Funding
Funding not disclosed
WSFounders
Product
Problem
Current methods for diagnosing Alzheimer's Disease, such as spinal taps and brain scans, are invasive, expensive, and may not be suitable for frequent monitoring. Early detection is critical for effective intervention, but these traditional approaches often identify the disease only after significant progression.
Solution
Superfluid Dx is developing a blood-based diagnostic platform that uses cell-free messenger RNA (cf-mRNA) technology to detect Alzheimer's Disease in its earliest stages. This minimally invasive liquid biopsy approach allows for the identification of the disease years before conventional diagnosis, potentially enabling timely intervention and personalized treatment options. The platform aims to replace or reduce the need for invasive procedures, offering a simpler method for ongoing monitoring of disease progression. By analyzing cf-mRNA in a single tube of blood, Superfluid Dx seeks to provide a more accessible and convenient diagnostic tool for Alzheimer's Disease.
Target Audience
The primary target audience includes individuals at risk of or suspected of having Alzheimer's Disease, as well as clinicians and researchers involved in the diagnosis and treatment of neurodegenerative diseases.
Features
- Utilizes cf-mRNA technology for early detection of Alzheimer's Disease.
- Minimally invasive blood test eliminates the need for spinal taps and brain scans.
- Enables repeat assessment of a patient’s disease state over time.
- Applicable to a wide variety of diseases, with an initial focus on Alzheimer's Disease.